LLY - Eli Lilly and Company
Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026PR NewswireINDI
Sofetabart mipitecan (Sofe-M) in combination with bevacizumab demonstrated a 79% confirmed objective response rate and 100% disease control rate, with similar activity observed across FR α expression levels Clinical activity with Sofe-M was maintained even in patients with prior PARP inhibitor exposure, patients who typically experience poor outcomes with platinum-based chemotherapy Sofe-M is currently being studied in both platinum-sensitive and platinum-resistant ovarian cancer in multiple Phase 3 studies as part of the FRAmework-01 master protocol INDIANAPOLIS, Oct. 24, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new Phase 1 data showing that its investigational folate receptor alpha (FRα) antibody-drug conjugate (ADC) sofetabart mipitecan (Sofe-M) plus bevacizumab achieved a confirmed objective response rate (cORR) of 79% and a disease control rate (DCR) of 100% in patients with platinum-sensitive ovarian cancer (PSOC). A cORR of 79% or higher was seen in both poly (ADP-ribose) polymerase inhibitor (PARPi)-treated and PARPi-naïve patients.
Eli Lilly chair and CEO Dave Ricks discusses the company's expansion and 150th year in business on ‘Claman's Power Players.' #fox #foxbusiness #media #breakingnews #us #usa #new #news #breaking #clamanspowerplayers #lizclaman #claman #elililly #davericks #ricks #weightloss #weightlossdrugs #obesity #obesitytreatment #glp1 #pharmaceuticals #pharma #pharmaceuticalindustry #healthcare #healthcareinnovation #drugdevelopment #artificialintelligence #ai #aitechnology #biotech #biotechnology #medicalresearch #medicine #business #businessnews #innovation #technology #drugdiscovery #healthtech #ceo #corporateexpansion
Axsome Therapeutics should expand its approved lineup while not facing the threat of generic competition through 2036. Eli Lilly is a leader in its core market and could diversify its lineup over the long run.
Diabetes and obesity-drug maker Eli Lilly (LLY) traded at $1,284.51, down approximately 1.70% at 10.09am EST, on October 23. With earnings due next Thursday, ac
Eli Lilly reaches a record high ahead of earnings, strengthening its bullish trend as technical signals point toward potential upside targets between $1,384 and $1,406.
A UBS portfolio manager sees three technology waves pushing stocks far beyond Wall Street's consensus, but his bullish case runs straight through two more Fed rate hikes that most investors are not pricing in.
First Lilly site to produce both active pharmaceutical ingredients and finished medicines in a fully integrated facility Site will create 650 high-wage jobs INDIANAPOLIS, Oct. 22, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) broke ground today on a new $5 billion manufacturing facility just west of Richmond, Virginia, in Goochland County, one of 10 new U.S. manufacturing sites announced since 2020 and one of five among them that will produce active pharmaceutical ingredients (API). As part of the company's more than $50 billion push to expand medicine production in the U.S., the Richmond site will be Lilly's first to produce both API and finished medicines in a fully integrated facility, with dedicated API capacity for bioconjugate and large-molecule medicines.
Bristol Myers Squibb (BMY -0.91%) primarily generates its revenue by developing and selling prescription therapeutic medications for oncology and cardiovascular health worldwide.
Boyd Wealth Management LLC purchased a new position in shares of Eli Lilly and Company (NYSE: LLY) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 449 shares of the company's stock, valued at approximately $520,000. Several other hedge funds
Bank Pictet and Cie Europe AG lowered its stake in Eli Lilly and Company (NYSE: LLY) by 16.3% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 37,664 shares of the company's stock after selling 7,313 shares during the quarter.
Diversify Advisory Services LLC lifted its stake in shares of Eli Lilly and Company (NYSE: LLY) by 7.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 17,956 shares of the company's stock after acquiring an additional 1,272 shares during
Novo Nordisk's CagriSema delivers 25% weight loss in women, spotlighting three ETFs for diversified exposure to the sector's growth.
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Business is booming, and the pipeline of new treatments is robust.
A European regulatory endorsement for an oral obesity pill is lifting Eli Lilly (NYSE:LLY | LLY Price Prediction) stock ahead of the rest of the drug group. Eli Lilly stock is up 4% to $1,295.
As of 11:36 AM ET, the Dow Jones Industrial Average (^DJI +0.98%) is up 0.91% to 52,437 as blue-chips outperform, while the S&P 500 (^GSPC +0.46%) has climbed 0.31% to 7,715 and the Nasdaq Composite (^IXIC +0.28%) is up 0.08% to 26,460.
The Dow and Russell 2000 are leading the way today as an oil price pivot sends stocks confidently higher
Eli Lilly just posted 47.7% revenue growth and its weight-loss drugs are reshaping global healthcare, but whether that momentum turns a four-year investment into a windfall or a disappointment depends on factors most investors overlook.
In the latest trading session, Eli Lilly (LLY) closed at $1, marking a -1.33% move from the previous day.